부산대학교 도서관

First, patients with DLBCL receiving BCR inhibitors are typically treated simultaneously with multiagent immunochemotherapy regimens, making it hard to establish which mutations provide resistance to which agent, or indeed if sensitivity to the BCR inhibitor ever existed in the first place. These preclinical observations suggest a role for the targeted inhibitors of the BCR pathway in the treatment of DLBCL.[1] DLBCL is most commonly present as malignant infiltration of lymph nodes. Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma that is molecularly and clinically heterogeneous. [Extracted from the article]